PMID- 30915750
OWN - NLM
STAT- MEDLINE
DCOM- 20200813
LR  - 20200813
IS  - 2284-0729 (Electronic)
IS  - 1128-3602 (Linking)
VI  - 23
IP  - 5
DP  - 2019 Mar
TI  - MEG3 inhibits cell proliferation, invasion and epithelial-mesenchymal transition 
      in laryngeal squamous cell carcinoma.
PG  - 2062-2068
LID - 17247 [pii]
LID - 10.26355/eurrev_201903_17247 [doi]
AB  - OBJECTIVE: Dysregulation of long non-coding RNAs (lncRNAs) is associated with 
      human carcinogenesis. The aim of the study is to explore the biological functions 
      of MEG3 expression in laryngeal squamous cell carcinoma (LSCC). PATIENTS AND 
      METHODS: QRT-PCR analysis was performed to assess the expression of MEG3 in 35 
      pairs of LSCC tissues and adjacent non-cancerous tissues. Cell proliferation, 
      cell migration, and cell invasion capacities were determined by CCK8 assay and 
      transwell assay in Hep-2 cell. QRT-PCR and Western blot analysis were applied to 
      detect the relative expression of Twist1, E-cadherin and Vimentin in Hep-2 cells. 
      RESULTS: In the study, our results showed that MEG3 expression was significantly 
      lower in tumor tissues compared with that in adjacent non-cancerous tissues. 
      Lower MEG3 expression was significantly associated with lymph node metastasis and 
      advanced TNM stage of patients. Knockdown of MEG3 significantly promotes cell 
      proliferation, cell migration, cell invasion and Epithelial-Mesenchymal 
      Transition (EMT) process by upregulating Twist1 and Vimentin expression and 
      reducing E-cadherin expression in Hep-2 cell. Conversely, upregulation of MEG3 
      had the inhibiting effects in Hep-2 cell. CONCLUSIONS: These results suggested 
      that MEG3 may serve as a novel potentially therapeutic target for LSCC treatment.
FAU - Zhao, Y-Q
AU  - Zhao YQ
AD  - Department of Otolaryngology, Daqing Oil Field General Hospital, Daqing, China. 
      xuhuixuhui11@126.com.
FAU - Liu, X-B
AU  - Liu XB
FAU - Xu, H
AU  - Xu H
FAU - Liu, S
AU  - Liu S
FAU - Wang, J-M
AU  - Wang JM
LA  - eng
PT  - Journal Article
PL  - Italy
TA  - Eur Rev Med Pharmacol Sci
JT  - European review for medical and pharmacological sciences
JID - 9717360
RN  - 0 (Antigens, CD)
RN  - 0 (CDH1 protein, human)
RN  - 0 (Cadherins)
RN  - 0 (MEG3 non-coding RNA, human)
RN  - 0 (Nuclear Proteins)
RN  - 0 (RNA, Long Noncoding)
RN  - 0 (TWIST1 protein, human)
RN  - 0 (Twist-Related Protein 1)
RN  - 0 (VIM protein, human)
RN  - 0 (Vimentin)
SB  - IM
MH  - Antigens, CD/genetics/metabolism
MH  - Cadherins/genetics/metabolism
MH  - Carcinoma, Squamous Cell/genetics/*pathology
MH  - Cell Movement
MH  - Cell Proliferation
MH  - *Down-Regulation
MH  - Epithelial-Mesenchymal Transition
MH  - Female
MH  - Gene Expression Regulation, Neoplastic
MH  - Hep G2 Cells
MH  - Humans
MH  - Laryngeal Neoplasms/genetics/*pathology
MH  - Lymphatic Metastasis
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Invasiveness
MH  - Neoplasm Staging
MH  - Nuclear Proteins/genetics/metabolism
MH  - RNA, Long Noncoding/*genetics
MH  - Twist-Related Protein 1/genetics/metabolism
MH  - Vimentin/genetics/metabolism
EDAT- 2019/03/28 06:00
MHDA- 2020/08/14 06:00
CRDT- 2019/03/28 06:00
PHST- 2019/03/28 06:00 [entrez]
PHST- 2019/03/28 06:00 [pubmed]
PHST- 2020/08/14 06:00 [medline]
AID - 17247 [pii]
AID - 10.26355/eurrev_201903_17247 [doi]
PST - ppublish
SO  - Eur Rev Med Pharmacol Sci. 2019 Mar;23(5):2062-2068. doi: 
      10.26355/eurrev_201903_17247.